Every 8-K that Aptose Biosciences, Inc. (APTO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow APTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full APTO filings page.
Aptose Biosciences (APTO) said it conducted a competitive selection to choose its independent registered public accounting firm for the fiscal year ending December 31, 2025. KPMG LLP agreed to continue reviewing the company’s interim quarterly financial results through the first two fiscal quarters of 2025. The filing includes a letter from KPMG LLP to the SEC and is signed by William G. Rice, Ph.D., President and CEO.
Aptose Biosciences Inc. reported new retention award agreements for three senior executives that would pay cash bonuses if the company undergoes a qualifying change of control. The agreements cover CEO William Rice, CFO Fletcher Payne, and Chief Medical Officer Rafael Bejar. Dr. Rice’s retention grant is $331,496.00, Mr. Payne’s is $167,058.67, and Dr. Bejar’s is $199,946.67. Each amount would be paid within five days after the closing of a defined change of control, but only if the executive is still considered “Actively Employed” at that time.
Aptose Biosciences Inc. held its reconvened Annual and Special Meeting of shareholders on August 22, 2025, where investors voted on corporate matters. Shareholders approved the appointment of the Corporation’s independent registered public accounting firm for the fiscal year ended December 31, 2025, with 1,436,464 votes for (96.95%), 36,817 votes against (2.48%), 8,376 abstentions, and 2 broker non-votes. The company also furnished a press release as Exhibit 99.1 providing additional information, which is treated as furnished rather than filed for securities law purposes.
Aptose Biosciences Inc. filed a current report to note that on August 22, 2025 it issued a press release, which is attached as Exhibit 99.1. The company states that this press release is being furnished under a Regulation FD disclosure item and will not be treated as filed for liability purposes under the Securities Exchange Act or automatically incorporated into other securities law filings unless specifically referenced.
Aptose Biosciences Inc. filed a current report to furnish a company press release under Regulation FD. The report states that Aptose issued a press release dated August 18, 2025, which is attached as Exhibit 99.1 and incorporated by reference. The company also clarifies that this information is being furnished, not filed, for purposes of the Securities Exchange Act and the Securities Act, consistent with General Instruction B.2.
Aptose Biosciences Inc. disclosed in a Form 8-K that on August 13, 2025 it issued a press release reporting its results of operations and financial condition, which is furnished as Exhibit 99.1. The filing states the press release is furnished under General Instruction B.2 and therefore is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings except where expressly stated. The Form 8-K also provides a cover page interactive XBRL file as Exhibit 104. The report is signed by William G. Rice, Ph.D., Chairman, President and Chief Executive Officer.
Filing date: August 6, 2025. Aptose Biosciences, Inc. (APTO) filed a Form 8-K reporting a Regulation FD disclosure announcing a press release dated August 6, 2025, which is attached as Exhibit 99.1.
Regulatory note: The press release attached as Exhibit 99.1 is explicitly stated to not be deemed "filed" for purposes of Section 18 of the Exchange Act pursuant to General Instruction B.2. Item 9.01 lists Exhibit 99.1 (Press Release dated August 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).
Company details: Commission File No. 001-32001; EIN 98-1136802; principal executive office at 66 Wellington Street West, Suite 5300, TD Bank Tower, Box 48, Toronto, Ontario M5K 1E6, Canada; phone (647) 479-9828. No securities are registered under Section 12(b). The form is signed by William G. Rice, Ph.D., Chairman, President, and Chief Executive Officer, dated August 6, 2025.
Aptose Biosciences (NASDAQ:APTO) filed an 8-K disclosing a new US$8.5 million secured term loan agreement with Hanmi Pharmaceutical dated 20 Jun 2025.
Key terms:
- Facility available in up to 5 advances (≤US$2.5 m each) through 31 Dec 2025; non-revolving.
- Interest: 6% fixed; balloon repayment of all principal and accrued interest on 31 Aug 2028.
- Secured by first-ranking liens on all present and after-acquired property of Aptose and guaranteed by subsidiaries.
- Purpose limited to continued clinical development and operating costs related to Tuspetinib, an AML therapy.
- Contains customary covenants and default provisions; any re-borrowings prohibited.
The filing also triggers Item 2.03 for creation of a direct financial obligation. The debt adds leverage but supplies non-dilutive capital for ongoing trials.
Aptose Biosciences Inc. (NASDAQ: APTO) filed a Form 8-K dated June 20, 2025 to disclose an Item 7.01 Regulation FD communication. The filing states that the company issued a press release on the same date, attached as Exhibit 99.1.
The 8-K expressly notes that, under General Instruction B.2, the press release is being “furnished” rather than “filed”, meaning it is not incorporated into Exchange Act reports unless specifically referenced. No financial results, strategic transactions, or operational updates are contained in the 8-K itself, and the exhibit text is not included in the filing excerpt provided.
Aptose Biosciences Inc. (APTO) filed a Form 8-K dated June 18, 2025 to disclose the immediate resignation of director Carol Ashe, effective June 16, 2025.
The company states that Ms. Ashe’s departure was not related to any disagreement regarding operations, policies, or practices. Chairman, President & CEO William G. Rice, Ph.D. signed the filing on behalf of the board. No other management changes, financial data, or strategic transactions were reported.